Cortical event-related potentials in preclinical familial Alzheimer disease

Golob, Edward J.; Ringman, John M.; Irimajiri, Rie; Bright, S.; Schaffer, Barbara; Medina, Luis D.; Starr, Arnold

doi:10.1212/wnl.0b013e3181c1de77

Cited by 96 publications

(85 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It also greatly improved our understanding of the neurophysiological underpinnings of various clinical disorders. Nowadays, for example, auditory ERPs are being used to study the neurodevelopmental status of persons with language development problems [4], Alzheimer's disease [5], and autism [6].…”

Section: Introductionmentioning

confidence: 99%

An introduction to the measurement of auditory event-related potentials (ERPs)

Remijn

Hasuo

Fujihira

et al. 2014

Acoust. Sci. & Tech.

View full text Add to dashboard Cite

In 1939, Pauline Davis reported the first study on event-related potentials (ERPs) performed on awake humans. ERPs are time-locked brain potentials that occur in response to cognitive, motor or perceptual events. The events used by Davis were sounds, and in the decades that followed her landmark study ERP research significantly contributed to the knowledge of auditory perception and neurophysiology we have today. ERPs are very well suited to study neural responses to sound stimuli, since the researcher can monitor the brain's registration of sound edges and spectral changes in sound on a millisecond-by-millisecond basis. In this overview we will introduce basic concepts of auditory ERP research. The overview includes descriptions of typical ERP components, experimental paradigms, sound stimuli, research methodology, and ways to analyze data.

show abstract

Section: Introductionmentioning

confidence: 99%

An introduction to the measurement of auditory event-related potentials (ERPs)

Remijn

Hasuo

Fujihira

et al. 2014

Acoust. Sci. & Tech.

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

“…7 Studies have proposed ERPs as a sensitive method for early detection of AD, separating EEG activity related to AD pathology from normal aging. [8][9][10][11][12] Preclinical markers and early detection are increasingly important as research on new treatments that may slow or halt decline in AD are under development. 13,14 Familial AD (FAD) allows the study of presymptomatic stages of AD that may be relevant for sporadic AD.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Event-related potential markers of brain changes in preclinical familial Alzheimer disease

Quiroz

Ally²,

Celone³

et al. 2011

Neurology

View full text Add to dashboard Cite

Objectives: Event-related potentials (ERPs) can reflect differences in brain electrophysiology underlying cognitive functions in brain disorders such as dementia and mild cognitive impairment. To identify individuals at risk for Alzheimer disease (AD) we used high-density ERPs to examine brain physiology in young presymptomatic individuals (average age 34.2 years) who carry the E280A mutation in the presenilin-1 (PSEN1) gene and will go on to develop AD around the age of 45.Methods: Twenty-one subjects from a Colombian population with familial AD participated: 10 presymptomatic subjects positive for the PSEN1 mutation (carriers) and 11 siblings without the mutation (controls). Subjects performed a visual recognition memory test while 128-channel ERPs were recorded.Results: Despite identical behavioral performance, PSEN1 mutation carriers showed less positivity in frontal regions and more positivity in occipital regions, compared to controls. These differences were more pronounced during the 200-300 msec period. Discriminant analysis at this time interval showed promising sensitivity (72.7%) and specificity (81.8%) of the ERP measures to predict the presence of AD pathology. Conclusions:Presymptomatic PSEN1 mutation carriers show changes in brain physiology that can be detected by high-density ERPs. The relative differences observed showing greater frontal positivity in controls and greater occipital positivity in carriers indicates that control subjects may use frontally mediated processes to distinguish between studied and unstudied visual items, whereas carriers appear to rely more upon perceptual details of the items to distinguish between them. These findings also demonstrate the potential usefulness of ERP brain correlates as preclinical markers of AD. Neurology Recognition memory impairments in Alzheimer disease (AD) have been linked to neocortical association areas including temporal and parietal lobes.1 Event-related potentials (ERPs) are less expensive, more widely available, and more comfortable than many other imaging modalities (e.g., MRI, PET, SPECT). ERPs, along with other EEG measures, have proven to be a useful marker in neurodegenerative conditions. 2-5 ERP components of recognition memory are sensitive to decline in old age 6 and amnestic mild cognitive impairment (aMCI). 7 Studies have proposed ERPs as a sensitive method for early detection of AD, separating EEG activity related to AD pathology from normal aging. [8][9][10][11][12] Preclinical markers and early detection are increasingly

show abstract

“…By inference, delayed P300 latencies (by 2SD) or reduced P300 amplitudes were considered features of dementia, and thus useful diagnostic tools [40]. Based on this method, several studies found delays or amplitude decreases of P300 recorded from posterior (Pz) derivations in patients with putative AD [41], subcortical dementia [42], metabolic disorders [43] e PDD [44]. Yet, dementia categorization in the last ten years has been revolutionized by the identification of DLB, representing from 25 to 43% of all dementia cases.…”

Section: P 300 Abnormalitiesmentioning

confidence: 99%

Is There a Place for Clinical Neurophysiology Assessments in Synucleinopathies?

Onofrj¹,

Bonanni²,

Thomas³

et al. 2011

Neuroimaging for Clinicians - Combining Research and Practice

View full text Add to dashboard Cite

IntroductionParkinson Disease (PD), Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA) are characterized by deposition of Lewy Bodies (LB), consisting of eosinophilic intracellular (intraneural in PD and DLB and intraglial in MSA) inclusions of -synuclein and allowing the three disorders to be categorized as synucleinopathies. The identification in the last two decades of specific clinical features of synucleinopathies has been a major breakthrough in Neurology, as it prompted a reconsideration of diagnostic and therapeutic approaches to dementia and parkinsonism. The recognition of synuclein and ubiquitin markers in dementia resulted in the reclassification of patients previously considered as affected by Alzheimer Disease (AD) and Vascular Dementia (VaD), and there is now agreement that DLB is the second most common cause of dementia in elderly population: its prevalence is reported to be in the 25-43% range in different studies. DLB is clinically characterized by the presence of prominently dysexecutive dementia (frontal lobe or subcortical dementia according to earlier classification [1]), cognitive fluctuations, consisting of remitting-relapsing episodes of blunted conscience reaching levels of stupor, by the occurrence of visual hallucinations and delusions, by parkinsonian motor signs and hypersensitivity to neuroleptic treatment, ranging from worsening of parkinsonism to the possible lethal neuroleptic-malignant syndromes [2]. Yet, variances of presentation and overlapping symptoms with AD and Fronto-Temporal lobe Degeneration (FTD), could be misleading in the process of addressing a clinical diagnosis with consequent therapeutic risks(e.g. introducing neuroleptic treatments in patient with DLB), or economic costs (e.g. addressing patients with DLB to treatment protocols dedicated to AD patients, based on vaccines or antibodies against amyloid proteins, a neuropathological feature of AD). It is evident the stringent need for improvement of reliable diagnostic tools (u.e. biomarkers) to differentiate the diseases associated with dementia. In 2010 the National Institute of Health, NIH, held a symposium focused on the development of possible biomarkers for DLB. Among the different suggested biomarkers, neurophysiological assessments were reconsidered, as a large amount of neurophysiological studies had been devoted to AD and PD, whose characteristics are shared by DLB. www.intechopen.com Neuroimaging for Clinicians -Combining Research and Practice 300We contributed to several studies on this argument along the years, and in the present chapter we discuss the role of clinical neurophysiological studies in DLB in comparison with other disorders. The essential background of our original studies laid in the fact that most historical studies were performed when the DLB clinical entity was unknown and therefore some of the past results were marred by absent recognition of this clinical entity. Synucleinopathies: Dementia with lewy bodiesSynucleinopathies comprise a diverse groups of neurodegenerati...

show abstract

Cortical event-related potentials in preclinical familial Alzheimer disease

Cited by 96 publications

References 36 publications

An introduction to the measurement of auditory event-related potentials (ERPs)

An introduction to the measurement of auditory event-related potentials (ERPs)

Event-related potential markers of brain changes in preclinical familial Alzheimer disease

Is There a Place for Clinical Neurophysiology Assessments in Synucleinopathies?

Contact Info

Product

Resources

About